{
  "pmcid": "11481812",
  "sha256": "47f7052d12eba9545e5455f21c22e6032773c45f0cfae542c7ff93d1ca3f9e27",
  "timestamp_utc": "2025-11-09T23:16:38.861376+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.905628930817613,
    "reading_ease": 28.757604821802943,
    "word_count": 265
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Fascial Plane Blocks in Chronic Pain Management"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included studies referencing 'fascial plane blocks' for chronic pain conditions such as persistent post-surgical, neuropathic, musculoskeletal-myofascial, and cancer-related pain."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Adverse events were rare, with mild side effects reported in 3% of the intervention group and 1% of the control group."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to evaluate their efficacy and safety in chronic pain treatment."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was pain reduction, measured using standard scales over a 12-week period."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation methods and allocation concealment were not specified in the included studies."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding of outcome assessors, patients, and clinicians was not consistently reported."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The effect size for pain reduction was significant, with a mean difference of 5.2 on the numeric rating scale (95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were rare, with mild side effects reported in 3% of the intervention group and 1% of the control group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}